Dup15q drug trial halted early: what happened?
NCT ID NCT05307679
First seen Jan 05, 2026 · Last updated May 15, 2026 · Updated 16 times
Summary
This study tested a drug called basmisanil in children aged 2 to 14 with Dup15q syndrome, a rare genetic condition that causes developmental delays. The goal was to see if the drug could improve daily living skills by targeting a specific brain receptor. Only 7 children enrolled, and the study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUP15Q SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital Los Angeles
Los Angeles, California, 90010, United States
-
Evelina London Children's Hospital
London, SE1 7EH, United Kingdom
-
Hospital Sant Joan De Deu
Esplugues de Llobregas, Barcelona, 08950, Spain
-
Hospital Universitario La Paz
Madrid, 28046, Spain
-
Rush University Medical Center
Chicago, Illinois, 60612-3244, United States
Conditions
Explore the condition pages connected to this study.